The National Health Insurance Fund (NHIF) has proposed to increase the reimbursement level for more than 400 medicinal products, grouped into 52 INN groups, indicated for the home treatment of chronic cardiovascular diseases. The proposal is supported by the Ministry of Health and the Ministry of Finance and will be implemented from April 2024, following ratification by the National Council on Prices and Reimbursement of Medicinal Products.
The NHIF estimates that more than 600,000 patients suffering from cardiovascular diseases will receive medicines from these groups free of charge or at reduced co-payments. The necessary funding for the amendment will be provided through the NHIF budget.
The decision to increase the reimbursement level for medicines for chronic cardiovascular diseases is in line with the NHIF’s long-term strategy to fully reimburse pharmaceuticals for socially important chronic diseases and to expand the group of medicinal products for which patients pay no or low co-payments.